The Point-of-Care Diagnostic Devices market is forecast to rise at a CAGR of 12.9%, climbing to USD 88.8 billion in 2031 from USD 48.4 billion in 2026.

The Point-of-Care Diagnostic Devices Market is growing as healthcare providers seek rapid testing solutions that deliver results near the patient. These devices enable faster diagnosis, immediate treatment decisions, and improved clinical workflow. Advances in portable diagnostic technologies and rising demand for decentralized healthcare are driving adoption across hospitals and clinics.

Description

Point-of-care diagnostic devices are medical testing systems intended to give diagnostic test results immediately to or near the patient's location. Unlike traditional laboratory testing, the end-user can perform diagnostic tests at various locations in their facility (i.e., hospitals, clinics, emergency rooms, homes). Common examples of point-of-care diagnostic devices are glucose monitoring systems, infectious disease detection, cardiac markers, and blood tests. Due to a greater need for faster clinical decision-making, an increase in incidence of chronic disease, and the growing demand for efficient management of patients, there has been an increase in point-of-care diagnostic testing. The advancements made in technology, such as biosensors, microfluidics and portable analyzers, have improved the accuracy, speed and usability of diagnostic devices, and expanded the roles of point-of-care diagnostic devices in the provision of healthcare.

Point-of-Care Diagnostic Devices Market Analysis

Growth Drivers

·      Increase in Chronic Disease Incidence: There is an increase in the number of persons diagnosed with chronic diseases, including diabetes, cardiovascular disease, and respiratory diseases, leading to a higher demand for the availability of quick and easy-to-use point-of-care diagnostic testing devices.

·      Increase in Demand for Quick Testing: In order to begin treatment as soon as possible, healthcare providers require rapid access to a patient's diagnostic test results. The use of point-of-care testing devices allows for faster access to results compared to waiting for the results to come back from the laboratory, thus providing better patient care and improving the workflow of clinicians.

·      Improvements in Diagnostic Technology: New technologies such as microfluidics and portable diagnostic testing devices have been developed and launched that have resulted in improved diagnostic accuracy and performance. As these devices become better and more accurate, the number of different tests that can be performed using point-of-care technology will continue to increase.

·      Increased Use of Telemedicine and Home Health Care: The growth of telemedicine and remote health care services has led to the increased use of portable diagnostic testing devices, enabling patients and their healthcare providers to monitor their health outside the four walls of a clinic.

Challenges and Opportunities

·      The point-of-care diagnostic devices market faces challenges related to regulatory compliance, quality assurance, and maintaining laboratory-level accuracy in portable devices. Limited training among healthcare professionals in some settings may also affect proper device usage. However, advancements in digital connectivity, artificial intelligence-assisted diagnostics, and improved biosensor technology are creating significant opportunities. Increasing demand for decentralised healthcare services and rapid diagnostic solutions is expected to drive continued innovation and broader adoption of point-of-care diagnostic devices worldwide.

Key Development

·      October 2025: Illumina, Inc. officially launched its 5-Base solution, a novel sequencing platform that enables simultaneous detection of both genomic variants and DNA methylation from a single sample workflow. The solution uses proprietary 5-base chemistry and enhanced DRAGEN analysis to deliver high-resolution insights into both the methylome and genome, streamlining epigenetic and genetic analysis for research and clinical applications. This development improves efficiency and reduces costs for epigenetic diagnostics, particularly in oncology and rare disease biomarker discovery, and positions dual omics testing as a scalable solution for clinical labs

Market Segmentation

The market is segmented by product type, test type, distribution channel and geography.

By Product Type: Glucose Monitoring Devices

Glucose monitoring devices are an important aspect of diagnostic point-of-care products, as they allow for the quick measurement of blood sugar levels to treat diabetes. Glucose monitoring devices are used in hospitals, clinics and people's homes to provide regular monitoring of blood sugar levels. They allow immediate clinical decision-making through portable devices that produce results quickly, which allows effective management of the disease. With the rising number of people being diagnosed with diabetes, there is a growing need for glucose monitoring devices. As technology continues to improve with regard to sensor accuracy, device accuracy, and ease of use, glucose monitoring devices will see even more growth in both clinical and non-clinical settings.

By Technology: Lateral Flow Assays

Lateral flow assays are widely utilized by point-of-care diagnostic devices because they are capable of providing quick, simple, inexpensive testing. Lateral flow assays are used to detect specific biomarkers found in sample sizes of blood, urine and saliva, with test results typically available in minutes. Lateral Flow Assays require minimal equipment to perform, making them a strong candidate for decentralized health care delivery. Lateral flow technology is being applied to the detection of infectious diseases, pregnancy testing, and many other rapid-screening applications. Innovations in the sensitivity and specificity of assays will continue to expand the reliability of diagnosing patients within point-of-care testing across many healthcare facilities and in remote settings.

By End User: Hospitals & Clinics

Hospitals and clinics represent the largest end-user group for point-of-care diagnostic devices because hospitals and clinics need a fast way to provide patient care and make immediate decisions when treating patients. Point-of-Care Diagnostic manufacturers provide medical professionals with the ability to perform diagnostic tests

Regional Analysis

North America Market Analysis

North America is the forerunner in the point-of-care diagnostics device market due to its high level of adoption of modern medical technology and strong healthcare systems. Many hospitals and clinics utilize portable diagnostic devices in order to provide immediate testing results to patients and more thoroughly monitor them.

South America Market Analysis

In South America, the point-of-care diagnostic device market is starting to grow because healthcare facilities are including portable diagnostic technologies in order to provide patients with greater access to testing services. Increased investment into healthcare infrastructure is foster growth.

Europe Market Analysis

In Europe, the point-of-care diagnostic device market has been growing steadily through increased demand for efficient diagnostic systems along with strong healthcare systems that utilize early detection of diseases and closely monitor patients.

Middle East and Africa Market Analysis

In the Middle East and Africa, healthcare facilities are beginning to utilize portable diagnostic systems in order to improve access to medical testing in underserved remote areas.

Asia Pacific Market Analysis

Asia-Pacific is one of the world's fastest growing regions for point-of-care diagnostic equipment due to healthcare infrastructure expansion rates, the growing prevalence of chronic illnesses, and increased demand for rapid diagnostic testing options.

List of Companies

·      Abbott Laboratories

·      Roche Diagnostics

·      Siemens Healthineers

·      Thermo Fisher Scientific

·      Becton Dickinson and Company

·      QuidelOrtho Corporation

·      Everlywell

·      LetsGetChecked

·      OraSure Technologies

·      Cue Health

Roche Diagnostics

Within its product offerings, one can find real-time PCR systems, high-throughput testing solutions, and companion diagnostics used for oncological, infectious diseases, and genetic testing. Its diagnostic technology facilitates laboratory automation and collaboration through integration with laboratory information systems, allowing for optimal workflows and data management. Roche also manufactures multiplex assays to enable the simultaneous detection of various pathogens. Furthermore, Roche's continuous investments in new technologies, including next-generation sequencing and biomarker discovery, are helping to solidify its role in the field of precision medicine. The breadth of Roche's portfolio and its global reach establish it as one of the leading diagnostic companies, helping to make it an essential component of clinical and reference labs.

Thermo Fisher Scientific

Thermo Fisher's Applied Biosystems brand manufactures and sells products that relate to genetic analysis, infectious disease identification, and research purposes. Additionally, Thermo Fisher's platforms provide high-throughput workflows, allowing labs to increase their testing capacity. Thermo Fisher also offers package solutions for integrated service/support to help labs achieve optimal assay performance and compliance. Thermo Fisher is well-known for its strong commitment to research and development in order to support ongoing innovation in testing and laboratory automation, positioning it to be a critical partner for clinical and research labs globally.

Point-of-Care Diagnostic Devices Market Scope: